ARCHIVES

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

Proposed Criteria For Establishing Carcinogenicity Listed

November 21, 1975

Avastin Improves Survival By 30 Percent In Advanced Non-Small Cell Lung Cancer

June 24, 2005

Screening Frequency for Cervical Cancer May Be Reduced, ACS Says

November 22, 2002

Arizona Cancer Center Seeks NCI Recognition As Comprehensive

May 29, 1987

In Brief: Hopkins Wins SPORE in Gastointenstinal Cancers; Nurses Group Calls For Proposals

January 21, 1994